CRP as a Biomarker for Pediatric Generalized Anxiety Disorder: What a Small Study Gets Right

Study at a Glance

This 2026 case-control study from Gazi University investigated whether serum inflammatory markers differ between drug-naïve children with GAD and healthy controls. The study is notable for its careful exclusion criteria: no obesity, no recent infections, no anti-inflammatory medications, and no comorbid psychiatric diagnoses. This design isolates the GAD-specific inflammatory profile as cleanly as a small study can.

Diagnosis was confirmed using the K-SADS-PL (DSM-5 version), and symptom severity was quantified with the Revised Child Anxiety and Depression Scales (RCADS). Seven biomarkers were measured: CRP (by nephelometry), IL-6 (electro-chemiluminescence), TNF-alpha, TWEAK, neopterin, IFN-gamma (all by ELISA), and zinc. The groups were well-matched on age, sex, BMI percentile, and family structure. The one notable demographic difference was a higher rate of family psychiatric history in the GAD group (56% vs 27%, p = 0.019).

Key Findings

The CRP difference is statistically significant with a small-to-moderate effect size (r = 0.32). The median GAD value of 1.7 mg/L falls in the cardiovascular risk stratification range considered indicative of low-grade systemic inflammation (1 to 3 mg/L), which puts it in the same territory where researchers and clinicians have increasingly been looking at inflammation as a contributor to chronic symptoms.

The Null Findings Are Informative

The absence of significant differences in IL-6, TNF-alpha, IFN-gamma, TWEAK, and neopterin is not simply a negative result. It helps build a picture of what kind of immune activity may or may not be happening in pediatric GAD specifically.

In comparison, IL-6 is significantly elevated in pediatric ADHD and schizophrenia. Neopterin has been found elevated in autism spectrum disorder, ADHD, and major depressive disorder. TWEAK behaves differently across conditions and even across symptom states within the same diagnosis. The pattern here suggests that GAD in children may involve a more contained, low-grade inflammatory process rather than the broader cytokine activation seen in other psychiatric conditions. That selective pattern across a well-designed cohort of “pure” GAD patients is itself a finding worth noting.

Duration Predicts Severity: A Clinically Relevant Correlation

One of the more clinically useful findings in this study is the strong positive correlation between time since symptom onset and anxiety symptom severity:

The median time since symptom onset in the GAD group was 11 months before diagnosis. Children who had been symptomatic longer had meaningfully higher anxiety scores. This is consistent with what most clinicians observe: GAD in children tends to be gradual and insidious, and untreated anxiety does not typically self-resolve at this stage of development.

Because this was a cross-sectional study, the direction of causality cannot be established. It is possible that more severe anxiety leads to longer delays in diagnosis, rather than (or in addition to) longer duration causing greater severity. Regardless of direction, the association reinforces the value of early identification. These children are being seen in offices by the time symptoms have often been present for nearly a year.

The Inflammation-Anxiety Connection: Where This Fits

The relationship between low-grade systemic inflammation and anxiety disorders has been building in the adult literature for over a decade. A recent meta-analysis confirmed that CRP is modestly but consistently elevated in GAD compared to healthy controls, and similar patterns have been observed in major depressive disorder. This study extends that finding into a pediatric, drug-naïve, comorbidity-free population with careful exclusion of confounders like obesity and anti-inflammatory medication use.

Several biological pathways have been proposed to explain how inflammation and anxiety interact. Inflammatory cytokines can cross or alter the blood-brain barrier, influence neurotransmitter synthesis and reuptake, activate the HPA axis, and modulate the gut-brain axis. Whether inflammation drives anxiety, anxiety drives inflammation, or the two are co-regulated through shared pathways remains an open question. What is increasingly clear is that they are not independent processes.

For practitioners already thinking about inflammatory contributors to pediatric mental health, this study adds a small but methodologically solid piece of evidence. The exclusion of obesity is particularly important: CRP rises with adiposity, and many previous studies in this space have been unable to cleanly separate the two. This cohort controlled for that directly.

How This Compares Across Pediatric Psychiatric Conditions

It is worth briefly contextualizing the GAD immune profile against what has been observed in other pediatric psychiatric diagnoses, because the differences are clinically informative:

The comparison illustrates that while CRP elevation appears relatively consistent across several internalizing disorders, the broader cytokine profile varies considerably. GAD appears to involve a more limited or contained immune response than conditions like ASD or MDD. This has implications for how we interpret inflammatory lab findings in children presenting with anxiety versus other psychiatric diagnoses.

Clinical Application: What This Does and Does Not Mean

The ROC analysis tells us clearly that CRP is not a useful screening tool for GAD in isolation. An AUC of 0.665 with sensitivity of 64% and specificity of 66% means it will miss a substantial number of true cases and flag many healthy children. No provider should be ordering CRP to diagnose or rule out GAD.

What this study does support is a different kind of clinical awareness. If a child with established or suspected anxiety also has a mildly elevated CRP without a clear infectious or metabolic explanation, the elevation may not be incidental. It may reflect the low-grade inflammatory state that appears to accompany GAD in some children. This context can:

For providers who already use dietary, lifestyle, or botanical interventions targeting inflammation as part of a pediatric anxiety protocol, this study provides some biological rationale for that approach. It does not prove that reducing inflammation will improve anxiety outcomes, but it is consistent with a model in which immune regulation and anxiety are interrelated.

The zinc trend (p = 0.073) is also worth noting for integrative practitioners. Zinc is involved in NMDA receptor activity, GABAergic function, and regulation of the HPA axis. Several trials have examined zinc supplementation in anxiety and ADHD with modest results. The trend toward lower zinc in the GAD group here aligns with that literature, though it did not reach statistical significance in this small sample.

Limitations to Keep in Mind

• Very small sample (25 cases, 30 controls). This is adequately powered for the primary CRP comparison, but underpowered to detect smaller differences in the other biomarkers, and too small to draw firm conclusions about null findings.
• Cross-sectional design. The study cannot determine whether elevated CRP precedes GAD onset, develops alongside it, or is a consequence of chronic stress and poor sleep that often accompany the disorder.
• Single-site, single-country recruitment from a tertiary psychiatry clinic. The sample may not represent community-level pediatric GAD, where presentations are often less severe.
• Lifestyle variables including sleep, diet quality, and physical activity were not formally measured. Although fasting conditions were standardized and obesity excluded, these factors can influence CRP and were not fully controlled.
• No established reference ranges exist for TWEAK and neopterin in pediatric populations, limiting the interpretability of those results beyond group comparisons.
• The study received a Grade C rating for scientific quality, novelty, and significance from peer reviewers. This does not mean the study is wrong, but it reflects the preliminary and exploratory nature of the findings.